What specific costs are being excluded in the non-GAAP reporting?

The non-GAAP reporting excludes two main categories of costs: 1) Incremental compensation payable to certain former Immunex employees under retention plans for a limited period. 2) Ongoing, non-cash amortization of intangible assets acquired as part of the Immunex acquisition, primarily related to Enbrel.

How does Amgen justify excluding the amortization of intangible assets?

Amgen justifies excluding the amortization of intangible assets (like Enbrel) by stating that it allows them to treat these acquired assets as if the company had developed them internally in the past. This approach, they believe, provides a supplemental measure of profitability that better reflects the ongoing operational performance without the non-cash impact of amortization, allowing for more consistent comparisons.

Are these non-GAAP measures replacing the standard GAAP financial results?

No, Amgen explicitly states that these historical non-GAAP financial measures are presented in addition to, not as a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). They are intended to provide supplementary information to investors.

AMGN 8-K SEC Disclosure

Q: What are the main reasons Amgen is using non-GAAP financial measures in this report?

Amgen is using non-GAAP financial measures to provide investors with a more comparable view of its operational performance. Specifically, they are excluding incremental compensation costs related to former Immunex employees under retention plans and the ongoing, non-cash amortization of intangible assets acquired from Immunex (such as Enbrel). The company believes these adjustments help to smooth out the impact of acquisition-related expenses and treat acquired intellectual property similarly to internally developed assets, aiding in period-to-period comparisons.

Summary

This 8-K filing from Amgen Inc. (AMGN), dated April 27, 2004, reports on the company's financial results for the first quarter ended March 31, 2004. A key aspect of this report is the company's use of non-GAAP financial measures, which they believe provide a more comparable view of their operational performance by excluding certain acquisition-related costs. Specifically, Amgen is adjusting its results to exclude incremental compensation for former Immunex employees under retention plans and the ongoing, non-cash amortization of intangible assets acquired in the Immunex acquisition, particularly related to Enbrel. The company uses these adjusted figures for internal budgeting and financial planning and believes they offer valuable supplementary information to investors for period-to-period comparisons, treating acquired assets similarly to internally developed ones.

Key Highlights

1Amgen reported its Q1 2004 financial results on April 22, 2004.
2The company is utilizing non-GAAP financial measures to present its results.
3Adjustments are made to exclude incremental compensation for former Immunex employees.
4Non-cash amortization of acquired intangible assets, notably related to Enbrel, is also excluded in non-GAAP reporting.
5Amgen believes these non-GAAP measures provide a clearer view of ongoing operational performance and facilitate comparisons.
6These adjusted figures are used internally for budgeting and financial planning.
7The company emphasizes that non-GAAP measures are supplementary to, and not a substitute for, GAAP reporting.

AMGEN INC 8-K Report (Apr 27, 2004)

Summary

Key Highlights

Frequently Asked Questions